Evaluation of Pre-Treatment Serum Levels of IL-7 and GM-CSF in Colorectal Cancer Patients
- PMID: 24551818
- PMCID: PMC3927386
Evaluation of Pre-Treatment Serum Levels of IL-7 and GM-CSF in Colorectal Cancer Patients
Abstract
Survival of Colorectal cancer (CRC) patients is considerably stage-dependent; therefore, early diagnosis is a pivotal factor in decreasing mortality and morbidity associated with this cancer. GM-CSF and IL-7 are reported to increase in different cancers and we aimed to investigate the pre-treatment serum levels of GM-CSF and IL-7 in Iranian patients with colorectal cancer. 127 patients (68 males and 59 females) entered this study before receiving chemotherapy or radiotherapy. A control group of 50 healthy age/sex matched individuals (27 males and 23 females) were included in the study. The serum levels of GM-CSF and IL-7 were measured using commercial enzyme linked immunosorbent assays. A significantly higher level of GM-CSF was found in the sera of patients with colorectal cancer compared to healthy age/sex matched controls (P=0.013). However, there was no significant difference between the levels of IL-7 in sera of patients and controls. We observed a significant elevation in the level of GM-CSF in poorly differentiated tumors (P=0.024). Also a significant correlation between lymphatic invasion and the level of GM-CSF in sera of CRC patients was detected (P=0.01). We found an increase of the level of IL-7 in four patients presenting moderate stages of tumor concomitant with a decrease of the level of GM-CSF. It can be concluded that the increase of the level of GM-CSF is accompanied by CRC progression in Iranian patients. Potential therapeutic effect of IL-7 in this disease, however, needs further investigations.
Keywords: Colorectal cancer; GM-CSF; IL-7; serum.
Figures


Similar articles
-
Serum levels of G-CSF and IL-7 in Iranian breast cancer patients.Asian Pac J Cancer Prev. 2012;13(10):5307-12. doi: 10.7314/apjcp.2012.13.10.5307. Asian Pac J Cancer Prev. 2012. PMID: 23244154
-
Implication of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Interleukin-3 (IL-3) in Children with Acute Myeloid Leukaemia (AML).Hematology. 2000;5(5):383-8. doi: 10.1080/10245332.2000.11746533. Hematology. 2000. PMID: 27420929
-
Serum granulocyte macrophage-colony stimulating factor: a tumor marker in colorectal carcinoma?Asian Pac J Cancer Prev. 2009;10(6):1021-4. Asian Pac J Cancer Prev. 2009. PMID: 20192576
-
Implication of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Interleukin-3 (IL-3) in Children with Acute Myeloid Leukaemia (AML); Malignancy.Hematology. 2001;5(5):383-388. Hematology. 2001. PMID: 11399637
-
Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.Bone Marrow Transplant. 1996 Jul;18(1):93-102. Bone Marrow Transplant. 1996. PMID: 8832001 Review.
Cited by
-
Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer.J Immunother Cancer. 2020 Oct;8(2):e000826. doi: 10.1136/jitc-2020-000826. J Immunother Cancer. 2020. PMID: 33106387 Free PMC article.
-
GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer.bioRxiv [Preprint]. 2023 Feb 7:2023.02.07.527499. doi: 10.1101/2023.02.07.527499. bioRxiv. 2023. Update in: Int J Mol Sci. 2023 Jun 29;24(13):10870. doi: 10.3390/ijms241310870. PMID: 36798357 Free PMC article. Updated. Preprint.
-
Systemic Interleukins' Profile in Early and Advanced Colorectal Cancer.Int J Mol Sci. 2021 Dec 23;23(1):124. doi: 10.3390/ijms23010124. Int J Mol Sci. 2021. PMID: 35008550 Free PMC article. Review.
-
Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types.Exp Mol Med. 2016 Jul 1;48(7):e242. doi: 10.1038/emm.2016.64. Exp Mol Med. 2016. PMID: 27364892 Free PMC article. Review.
-
Effects of intratumoral injection of immunoactivator after microwave ablation on antitumor immunity in a mouse model of hepatocellular carcinoma.Exp Ther Med. 2018 Feb;15(2):1914-1917. doi: 10.3892/etm.2017.5633. Epub 2017 Dec 14. Exp Ther Med. 2018. PMID: 29434784 Free PMC article.
References
-
- Boyle P, Leon ME. Epidemiology of colorectal cancer. Br Med Bull . 2002;64:1–25. - PubMed
-
- Whicher IT, Banks RE. Cytokines as tumour markers. Scand J Clin Lab Invest Suppl . 1995;221:122–44. - PubMed
-
- Demirci U, Coskun U, Sancak B, et al. Serum granulocyte macrophage-colony stimulating factor: a tumor marker in colorectal carcinoma? Asian Pac J Cancer Prev . 2009;10:1021–4. - PubMed
LinkOut - more resources
Full Text Sources